专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06293026B1 Method of measuring height of foot arch 失效
标题翻译：足弓高度测量方法
公开(公告)号：US06293026B1
公开(公告)日：2001-09-25
申请号：US09456576
申请日：1999-12-08
申请人： Eun K. Lee , Dong H. Kim , Hee T. Kim , Shin C. Kang , Young C. Kim , Sei K. Moon , Seong Y. Bae , Gyo T. Seo , Jong C. Lee , Choon K. Zhoh , Choong N. Cho , Jong S. Lee , Dae Y. Yang
发明人： Eun K. Lee , Dong H. Kim , Hee T. Kim , Shin C. Kang , Young C. Kim , Sei K. Moon , Seong Y. Bae , Gyo T. Seo , Jong C. Lee , Choon K. Zhoh , Choong N. Cho , Jong S. Lee , Dae Y. Yang
IPC分类号： A61B5107
CPC分类号： A43B7/28 , A43D1/022 , G01B1/00
摘要： A method of measuring the height of a foot arch precisely and easily using two essential heights of the foot arch is disclosed. In the method, a foot cast is primarily cast by pouring plaster into a foot mold. Thereafter, a first intersecting point and a second intersecting point are determined. The first intersecting point is determined by making a first line and a third line intersect. The second intersecting point is determined by making a second line and the third line intersect. The first line is a straight line extending from the center of the second toe to the center of the heel end. The second line is a straight line extending from the center of the big toe to a point spaced apart inwardly from the center of the heel end by ⅛ of the total distance of the heel end. The third line is a center line of the transverse arch of the foot. Finally, a first height and a second height are measured while the foot pattern is set in an upright position. The first height is defined between a flat base level and the first intersecting point, while the second height is defined between the base level and the second intersecting point.
摘要翻译：公开了一种使用足弓的两个基本高度精确且容易地测量足弓的高度的方法。在该方法中，脚浇铸主要是通过将石膏浇注到脚模中来铸造的。此后，确定第一交点和第二交点。通过使第一行和第三行相交来确定第一个相交点。通过制作第二行和第三行相交来确定第二个相交点。第一行是从第二脚趾的中心延伸到脚后跟中心的直线。第二行是从大脚趾的中心延伸到从脚跟端的中心向内分开的距离为脚跟端的总距离的直线。第三行是脚的横向拱的中心线。最后，在将脚图案设置在直立位置时，测量第一高度和第二高度。第一高度被限定在平坦的基准水平和第一个相交点之间，而第二个高度是在基准水平和第二个相交点之间定义的。

2. 发明授权

US5635351A Genetic gain and loss in gliomas 失效
标题翻译：神经胶质瘤的遗传增益和损失
公开(公告)号：US5635351A
公开(公告)日：1997-06-03
申请号：US403457
申请日：1995-03-14
申请人： Burt G. Feuerstein , Gayatry Mohapatra , Dong H. Kim
发明人： Burt G. Feuerstein , Gayatry Mohapatra , Dong H. Kim
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/156
摘要： The present invention provides chromosomal amplifications and deletions associated with neoplastic growth of gliomas. These amplifications and deletions may be used for detecting and grading gliomas. The invention also provides compositions for the detection of gliomas.
摘要翻译：本发明提供与神经胶质瘤的肿瘤生长相关的染色体扩增和缺失。这些扩增和缺失可用于检测和分级胶质瘤。本发明还提供用于检测胶质瘤的组合物。

3. 外观设计

USD378341S Hammer drill 失效
公开(公告)号：USD378341S
公开(公告)日：1997-03-11
申请号：US43189
申请日：1995-08-28
申请人： Dong H. Kim
设计人： Dong H. Kim

4. 发明授权

US4454291A N-(2-Substituted-1-oxoalkyl)-2,3-dihydro-1H-indole-2-carboxylic acid derivatives 失效
标题翻译： N-（2-取代的-1-氧代烷基）-2,3-二氢-1H-吲哚-2-羧酸衍生物
公开(公告)号：US4454291A
公开(公告)日：1984-06-12
申请号：US391080
申请日：1982-06-22
申请人： Dong H. Kim , Ronald J. McCaully
发明人： Dong H. Kim , Ronald J. McCaully
IPC分类号： C07D209/42 , C07D513/04
CPC分类号： C07D513/04 , C07D209/42 , Y02P20/55
摘要： Disclosed herein are 2,3-dihydro-1H-indole-2-carboxylic acids substituted on the nitrogen with 3-mercapto-2-alkyl-1-oxoalkyl, 3-phosphoryl-2-alkyl-1-oxopropyl, or 2-amino-2-alkyl-1-oxoalkyl derivatives which act as inhibitors of angiotensin converting enzyme and as antihypertensive agents. The compounds of the invention (excluding disclosed intermediates) have the general formula: ##STR1## wherein: n is 1 or 0;R.sub.1 is hydrogen, lower alkyl, aryl or aralkyl;R.sub.2 is hydrogen or lower alkyl;R.sub.3 is hydrogen, lower alkyl or aroyl;R.sub.5 is hydroxy, amino, or lower alkoxy;X is hydrogen, hydroxy, lower alkyl, lower alkoxy, or halogen;Y is hydrogen, lower alkyl, or aryl;Y is hydrogen, lower alkyl, or aryl;R.sub.4 is ##STR2## wherein: L is O, NR.sub.7 or S (where R.sub.7 is hydrogen or lower alkyl);M is R.sub.8, OR.sub.8, SR.sub.8, or NR.sub.9 R.sub.10 (where R.sub.8 is hydrogen, lower alkyl, aryl, or aralkyl; and R.sub.9 and R.sub.10 are, independently, hydrogen, lower alkyl, or aryl);A is O, NR.sub.13 or S;R.sub.11 and R.sub.12 are, independently, hydrogen, alkyl, aralkylor aryl;R.sub.13 is hydrogen or lower alkyl;m is 0, 1, 2, or 3;R.sub.20 is hydrogen or aryl; andR.sub.21 is hydroxy or lower alkoxy; or pharmaceutically acceptable salts thereof.Claimed compounds are intermediates of the formula: ##STR3## wherein R.sub.13 is hydrogen or lower alkyl; R.sub.14 is R.sub.5 or OZ, where R.sub.5 is hydroxy, amino, or lower alkoxy, and Z is a carboxylic acid protecting group.
摘要翻译：本文公开了在氮上与3-巯基-2-烷基-1-氧代烷基，3-磷酰基-2-烷基-1-氧代丙基或2-氨基取代的2,3-二氢-1H-吲哚-2-羧酸 -2-烷基-1-氧代烷基衍生物，其作为血管紧张素转化酶的抑制剂和抗高血压药。本发明的化合物（不包括所公开的中间体）具有以下通式：其中n为1或0; R1是氢，低级烷基，芳基或芳烷基; R2是氢或低级烷基; R3是氢，低级烷基或芳酰基; R5是羟基，氨基或低级烷氧基; X是氢，羟基，低级烷基，低级烷氧基或卤素; Y是氢，低级烷基或芳基; Y是氢，低级烷基或芳基; R 4是O，NR 7或S（其中R 7是氢或低级烷基）; M是R 8，OR 8，SR 8或NR 9 R 10（其中R 8是氢，低级烷基，芳基或芳烷基;且R 9和R 10独立地是氢，低级烷基或芳基）。 A为O，NR 13或S; R 11和R 12独立地为氢，烷基，芳烷基或芳基; R 13是氢或低级烷基; m为0,1,2或3; R 20是氢或芳基; 和R 21是羟基或低级烷氧基; 或其药学上可接受的盐。所要求的化合物是下式的中间体：其中R 13是氢或低级烷基; R14是R5或OZ，其中R5是羟基，氨基或低级烷氧基，Z是羧酸保护基。

5. 发明授权

US4350633A N-(2-Substituted-1-oxoalkyl)-2,3-dihydro-1H-indole-2-carboxylic acid derivatives 失效
标题翻译： N-（2-取代的-1-氧代烷基）-2,3-二氢-1H-吲哚-2-羧酸衍生物
公开(公告)号：US4350633A
公开(公告)日：1982-09-21
申请号：US284433
申请日：1981-07-20
申请人： Dong H. Kim , Ronald J. McCaully
发明人： Dong H. Kim , Ronald J. McCaully
IPC分类号： C07D209/42 , C07D513/04 , C07D209/04
CPC分类号： C07D513/04 , C07D209/42
摘要： Disclosed herein are 2,3-dihydro-1H-indole-2-carboxylic acids substituted on the nitrogen with 3-mercapto-2-alkyl-1-oxoalkyl, 3-phosphoryl-2-alkyl-1-oxopropyl, or 2-amino-2-alkyl-1-oxoalkyl derivatives which act as inhibitors of angiotensin converting enzyme and as antihypertensive agents. The compounds of the invention (excluding disclosed intermediates) have the general formula: ##STR1## wherein: n is 1 or 0;R.sub.1 is hydrogen, lower alkyl, aryl or aralkyl;R.sub.2 is hydrogen or lower alkyl;R.sub.3 is hydrogen, lower alkyl or aroyl;R.sub.5 is hydroxy, amino, or lower alkoxy;X is hydrogen, hydroxy, lower alkyl, lower alkoxy, or halogen;Y is hydrogen, lower alkyl, or aryl;Y is hydrogen, lower alkyl, or aryl;R.sub.4 is ##STR2## wherein: L is O, NR.sub.7 or S (where R.sub.7 is hydrogen or lower alkyl);M is R.sub.8, OR.sub.8, SR.sub.8, or NR.sub.9 R.sub.10 (where R.sub.8 is hydrogen, lower alkyl, aryl, or aralkyl; and R.sub.9 and R.sub.10 are, independently, hydrogen, lower alkyl, or aryl);A is O, NR.sub.13 or S;R.sub.11 and R.sub.12 are, independently, hydrogen, alkyl, aralkyl or aryl;R.sub.13 is hydrogen or lower alkyl;m is 0, 1, 2, or 3;R.sub.20 is hydrogen or aryl; andR.sub.21 is hydroxy or lower alkoxy;or pharmaceutically acceptable salts thereof.
摘要翻译：本文公开了在氮上与3-巯基-2-烷基-1-氧代烷基，3-磷酰基-2-烷基-1-氧代丙基或2-氨基取代的2,3-二氢-1H-吲哚-2-羧酸 -2-烷基-1-氧代烷基衍生物，其作为血管紧张素转化酶的抑制剂和抗高血压药。本发明的化合物（不包括所公开的中间体）具有以下通式：其中n为1或0; R1是氢，低级烷基，芳基或芳烷基; R2是氢或低级烷基; R3是氢，低级烷基或芳酰基; R5是羟基，氨基或低级烷氧基; X是氢，羟基，低级烷基，低级烷氧基或卤素; Y是氢，低级烷基或芳基; Y是氢，低级烷基或芳基; R 4是O，NR 7或S（其中R 7是氢或低级烷基）; M是R 8，OR 8，SR 8或NR 9 R 10（其中R 8是氢，低级烷基，芳基或芳烷基;且R 9和R 10独立地是氢，低级烷基或芳基）。 A为O，NR 13或S; R 11和R 12独立地为氢，烷基，芳烷基或芳基; R 13是氢或低级烷基; m为0,1,2或3; R 20是氢或芳基; 和R 21是羟基或低级烷氧基; 或其药学上可接受的盐。

6. 发明授权

US3940395A 4-Amino-2-phenyl-6-thiopryimidines 失效
标题翻译： 4-氨基-2-苯基-6-硫代嘧啶
公开(公告)号：US3940395A
公开(公告)日：1976-02-24
申请号：US137060
申请日：1971-04-23
申请人： Arthur A. Santilli , Dong H. Kim
发明人： Arthur A. Santilli , Dong H. Kim
IPC分类号： C07D239/30 , C07D239/46 , C07D239/54 , C07D239/40
CPC分类号： C07D239/46 , C07D239/30 , C07D239/54
摘要： The invention is directed to 4-amino-2-phenyl-6-thiopyrimidine compounds having the formula ##SPC1##Where R.sup.1 -R.sup.3 are as defined in the specification. The compounds have pharmacodynamic activity as central nervous system depressants. That is, they produce a calming effect in the host.
摘要翻译：本发明涉及具有下式的4-氨基-2-苯基-6-硫代嘧啶化合物，其中R 1 -R 3如说明书中所定义。该化合物具有作为中枢神经系统抑制剂的药效学活性。也就是说，它们在主机中产生平静的效果。

7. 外观设计

USD447636S1 Brush handle 失效
公开(公告)号：USD447636S1
公开(公告)日：2001-09-11
申请号：US29124781
申请日：2000-06-12
申请人： Dong H. Kim
设计人： Dong H. Kim

8. 外观设计

USD373112S Magnetic contactor 失效
公开(公告)号：USD373112S
公开(公告)日：1996-08-27
申请号：US27522
申请日：1994-08-23
申请人： Dong H. Kim
设计人： Dong H. Kim

9. 发明授权

US4593100A 3A,4,7,7a-tetrahydro-3,6,7a-trimethyl-4-substituted phenyl-isoxazolo[5,4-b]pyridine-5-carboxylic acid esters 失效
标题翻译： 3A，4,7,7a-四氢-3,6,7a-三甲基-4-取代的苯基 - 异恶唑并[5,4-b]吡啶-5-甲酸酯
公开(公告)号：US4593100A
公开(公告)日：1986-06-03
申请号：US684884
申请日：1984-12-21
申请人： Dong H. Kim
发明人： Dong H. Kim
IPC分类号： C07D498/04
CPC分类号： C07D498/04
摘要： Disclosed herein are 4-phenyl-tetrahydro-isoxazolo[5,4-b]-pyridine-5-carboxylic acid esters of Formula I: ##STR1## wherein Ar is phenyl or phenyl substituted by a halogen, nitro, or trifluoromethyl group; R.sup.1 is C.sub.1-3 alkyl; and R.sup.2 is C.sub.1-5 alkyl, (C.sub.1-5) alkoxy (C.sub.1-3)-alkyl, or mono- or di(C.sub.1-5) alkylamino (C.sub.1-3)alkyl;or physiologically acceptable acid addition salts thereof. The compounds of the invention exhibit calcium antagonist and antihypertensive properties in standard pharmacological procedures.
摘要翻译：本文公开了式I的4-苯基 - 四氢 - 异恶唑并[5,4-b] - 吡啶-5-甲酸酯：其中Ar是苯基或被卤素，硝基或三氟甲基取代的苯基; R1是C1-3烷基; 和R 2是C 1-5烷基，（C 1-5）烷氧基（C 1-3） - 烷基或单或二（C 1-5）烷基氨基（C 1-3）烷基; 或其生理上可接受的酸加成盐。本发明化合物在标准药理学过程中显示出钙拮抗剂和抗高血压药物。

10. 发明授权

US4454292A N-[2-Substituted-1-oxoalkyl]-2,3-dihydro-1H-indole-2-carboxylic acid derivatives 失效
标题翻译： N- [2-取代的-1-氧代烷基] -2,3-二氢-1H-吲哚-2-羧酸衍生物
公开(公告)号：US4454292A
公开(公告)日：1984-06-12
申请号：US391081
申请日：1982-06-22
申请人： Dong H. Kim , Ronald J. McCaully
发明人： Dong H. Kim , Ronald J. McCaully
IPC分类号： C07D209/42 , C07D513/04
CPC分类号： C07D513/04 , C07D209/42
摘要： Disclosed herein are 2,3-dihydro-1H-indole-2-carboxylic acids substitued on the nitrogen with 3-mercapto-2-alkyl-1-oxoalkyl, 3-phosphoryl-2-alkyl-1-oxopropyl, or 2-amino-2-alkyl-1-oxoalkyl derivatives which act as inhibitors of angiotensin converting enzyme and as antihypertensive agents. The compounds of the invention (excluding disclosed intermediates) have the general formula: ##STR1## wherein: n is 1 or 0;R.sub.1 is hydrogen, lower alkyl, aryl or aralkyl;R.sub.2 is hydrogen or lower alkyl;R.sub.3 is hydrogen, lower alkyl or aroyl;R.sub.5 is hydroxy, amino, or lower alkoxy;X is hydrogen, hydroxy, lower alkyl, lower alkoxy, or halogen; Y is hydrogen, lower alkyl, or aryl;Y is hydrogen, lower alkyl, or aryl;R.sub.4 is ##STR2## wherein: L is O, NR.sub.7 or S (where R.sub.7 is hydrogen or lower alkyl);M is R.sub.8, OR.sub.8, SR.sub.8, or NR.sub.9 R.sub.10 (where R.sub.8 is hydrogen, lower alkyl, aryl, or aralkyl; and R.sub.9 and R.sub.10 are, independently, hydrogen, lower alkyl, or aryl);A is O, NR.sub.13 or S;R.sub.11 and R.sub.12 are, independently, hydrogen, alkyl, aralkylor aryl;R.sub.13 is hydrogen or lower alkyl;m is 0, 1, 2, or 3;R.sub.20 is hydrogen or aryl; andR.sub.21 is hydroxy or lower alkoxy; or pharmaceutically acceptable salts thereof.Claimed compounds are intermediates of the formula: ##STR3## wherein R.sub.15 is hydrogen or lower alkyl.
摘要翻译：本文公开的是在氮上取代有3-巯基-2-烷基-1-氧代烷基，3-磷酰基-2-烷基-1-氧代丙基或2-氨基的2,3-二氢-1H-吲哚-2-羧酸 -2-烷基-1-氧代烷基衍生物，其作为血管紧张素转化酶的抑制剂和抗高血压药。本发明的化合物（不包括所公开的中间体）具有以下通式：其中n为1或0; R1是氢，低级烷基，芳基或芳烷基; R2是氢或低级烷基; R3是氢，低级烷基或芳酰基; R5是羟基，氨基或低级烷氧基; X是氢，羟基，低级烷基，低级烷氧基或卤素; Y是氢，低级烷基或芳基; Y是氢，低级烷基或芳基; R 4是O，NR 7或S（其中R 7是氢或低级烷基）; M是R 8，OR 8，SR 8或NR 9 R 10（其中R 8是氢，低级烷基，芳基或芳烷基;且R 9和R 10独立地是氢，低级烷基或芳基）。 A为O，NR 13或S; R 11和R 12独立地为氢，烷基，芳烷基或芳基; R 13是氢或低级烷基; m为0,1,2或3; R 20是氢或芳基; 和R 21是羟基或低级烷氧基; 或其药学上可接受的盐。所要求的化合物是下式的中间体：其中R 15是氢或低级烷基。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式